BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1397011)

  • 1. Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1992 Jun; 216(2):243-7. PubMed ID: 1397011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
    Waldmeier PC
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1990 May; 180(2-3):297-304. PubMed ID: 2365007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
    Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
    Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB
    Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.
    Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA
    Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
    Bieck PR
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase inhibitors and the cheese effect.
    Anderson MC; Hasan F; McCrodden JM; Tipton KF
    Neurochem Res; 1993 Nov; 18(11):1145-9. PubMed ID: 8255365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G; Finberg JP; Youdim MB
    Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanism of inhibition by chlorgyline and deprenyl of tyramine deamination by mitochondrial monoamine oxidase of rat liver].
    Deverina IS
    Biokhimiia; 1980 Oct; 45(10):1897-908. PubMed ID: 6786369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
    Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
    Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase (MAO)-A but not MAO-B inhibitors potentiate tyramine-induced catecholamine release from PC12 cells.
    Youdim MB
    J Neurochem; 1990 Feb; 54(2):411-4. PubMed ID: 2299343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ; Yu PH
    Psychopharmacology (Berl); 1989; 98(2):265-8. PubMed ID: 2502797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat.
    Benedetti MS; Boucher T; Carlsson A; Fowler CJ
    Biochem Pharmacol; 1983 Jan; 32(1):47-52. PubMed ID: 6830619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR; Antonin KH
    J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evidence for the reversible action of the monoamine oxidase inhibitor brofaromine on 5-hydroxytryptamine release in rat brain.
    Bel N; Artigas F
    Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):475-82. PubMed ID: 7543977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
    Alemany R; Olmos G; García-Sevilla JA
    Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of protein denaturing reactions on retardation of the activity of rat liver mitochondrial monoamine oxidase by clorgyline and deprenyl].
    Severina IS
    Biokhimiia; 1983 Sep; 48(9):1513-21. PubMed ID: 6414536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.